Hospital
Newyork-Presbyterian-Queens
Newyork-Presbyterian-Queens was paid $116.41M by Medicaid between Jan 2018 and Dec 2024, across 630 billing codes. Its largest line is 99283, emergency room visit (moderate) — 8.9% of everything it billed.
33Billing provider infoNEWYORK-PRESBYTERIAN-QUEENS
FLUSHING, NY 11355
FLUSHING, NY 11355
33aNPI1952347205assigned 06/22/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$116.41M
24GClaims2,201,781
24DCodes billed630
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#13 of 231
Median peer was paid$561K
This provider vs. median208×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,236 | $1.00M | |
| 2019 | 179,193 | $8.38M | |
| 2020 | 383,412 | $18.05M | |
| 2021 | 409,407 | $19.90M | |
| 2022 | 414,508 | $23.06M | |
| 2023 | 462,136 | $26.88M | |
| 2024incomplete | 328,889 | $19.15M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.9% | 60,840 | 58,098 | $10.35M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.6% | 58,201 | 51,046 | $8.85M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 6.0% | 42,400 | 8,725 | $7.04M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.7% | 32,367 | 31,618 | $5.48M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.7% | 34,320 | 33,183 | $5.45M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.1% | 31,986 | 26,655 | $4.74M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.7% | 11,262 | 10,815 | $3.14M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.2% | 33,423 | 10,962 | $2.58M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.2% | 15,885 | 15,243 | $2.51M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 14,642 | 13,865 | $2.44M |
| 93975 | 1.9% | 4,407 | 4,322 | $2.25M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 7,623 | 7,549 | $2.16M |
618 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 7,536 | $2.03M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.7% | 25,283 | $1.94M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.5% | 2,736 | $1.71M |
| 93458 | 1.3% | 859 | $1.54M | |
| 59025 | Fetal non-stress test | 1.2% | 6,345 | $1.37M |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 57,278 | $1.29M |
| 77412 | 1.1% | 3,892 | $1.24M | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.0% | 8,787 | $1.17M |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,261 | $1.16M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 8,161 | $1.14M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,321 | $1.09M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 37,822 | $1.05M |
| 76770 | <1% | 2,333 | $1.02M | |
| 87581 | <1% | 27,043 | $1.01M | |
| 93970 | <1% | 1,609 | $985K | |
| 77336 | <1% | 2,400 | $931K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 6,755 | $928K |
| 47562 | <1% | 313 | $898K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 13,061 | $881K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,802 | $711K |
| 86850 | <1% | 17,315 | $710K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 71,736 | $688K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,087 | $648K |
| 80053 | Comprehensive metabolic panel | <1% | 41,712 | $648K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 4,384 | $643K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 10,866 | $641K |
| 12001 | <1% | 1,240 | $623K | |
| 77387 | <1% | 1,352 | $614K | |
| 54161 | <1% | 553 | $605K | |
| 86901 | <1% | 22,078 | $593K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,691 | $589K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 5,892 | $557K |
| 12011 | <1% | 1,074 | $551K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 26,929 | $549K |
| 87486 | <1% | 27,035 | $527K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 16,828 | $526K |
| J0178 | Injection, aflibercept, 1 mg | <1% | 3,543 | $518K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,244 | $510K |
| 80076 | <1% | 40,414 | $504K | |
| 86900 | <1% | 21,584 | $499K | |
| 92551 | <1% | 5,624 | $487K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 3,865 | $466K |
| 97161 | <1% | 3,799 | $463K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 3,218 | $454K |
| 88342 | <1% | 7,641 | $428K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 3,105 | $414K |
| 80061 | Lipid panel | <1% | 23,246 | $386K |
| 87507 | <1% | 3,103 | $383K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 412 | $362K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,307 | $351K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 2,074 | $349K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 17,006 | $345K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,230 | $344K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 1,165 | $337K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 12,685 | $322K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 9,007 | $321K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,116 | $314K |
| 19281 | <1% | 325 | $314K | |
| 64483 | <1% | 565 | $278K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,816 | $270K |
| 90686 | <1% | 14,455 | $259K | |
| 99381 | <1% | 1,828 | $259K | |
| 99173 | <1% | 5,966 | $258K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,483 | $256K |
| 92134 | <1% | 4,070 | $252K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 20,960 | $229K |
| 76801 | <1% | 2,061 | $224K | |
| 94010 | <1% | 2,271 | $218K | |
| 29540 | <1% | 847 | $216K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,079 | $209K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,023 | $209K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,084 | $208K |
| 88142 | <1% | 7,906 | $207K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,454 | $207K |
| 96367 | <1% | 5,214 | $197K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,668 | $192K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 272 | $189K |
| 19125 | <1% | 102 | $187K | |
| 92202 | <1% | 3,179 | $185K | |
| 97165 | <1% | 1,552 | $184K | |
| 99205 | Prolong outpt/office vis | <1% | 1,216 | $182K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 12,972 | $173K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,369 | $172K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,521 | $168K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 877 | $166K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 6,323 | $153K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,166 | $153K |
| 92133 | <1% | 2,195 | $151K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,043 | $150K |
| 83880 | <1% | 5,029 | $149K | |
| 77334 | <1% | 378 | $148K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,326 | $145K |
| 88341 | <1% | 3,866 | $143K | |
| 76098 | <1% | 619 | $141K | |
| 90715 | <1% | 6,115 | $138K | |
| 92526 | <1% | 957 | $132K | |
| 19301 | <1% | 56 | $132K | |
| 20610 | <1% | 1,331 | $132K | |
| 10E0XZZ | <1% | 171 | $127K | |
| 19083 | <1% | 82 | $125K | |
| 12002 | <1% | 253 | $125K | |
| 11721 | <1% | 2,417 | $124K | |
| 92083 | <1% | 2,013 | $122K | |
| 86480 | <1% | 3,290 | $122K | |
| 99385 | <1% | 894 | $120K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,545 | $120K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 23,023 | $119K |
| 86769 | <1% | 3,710 | $117K | |
| J3490 | Unclassified drugs | <1% | 805 | $116K |
| 88307 | <1% | 1,581 | $110K | |
| 44970 | <1% | 40 | $108K | |
| 87631 | <1% | 1,627 | $106K | |
| J0878 | Injection, daptomycin, 1 mg | <1% | 2,050 | $105K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 731 | $102K |
| 77300 | <1% | 412 | $99K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,061 | $99K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 10,529 | $99K |
| 87536 | <1% | 1,188 | $98K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 187 | $98K |
| 96161 | <1% | 2,518 | $98K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,795 | $97K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 614 | $93K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,035 | $92K |
| 83655 | <1% | 8,822 | $90K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,660 | $89K |
| D1110 | Prophylaxis - adult | <1% | 2,700 | $89K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 2,061 | $88K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,829 | $86K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 16,768 | $86K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 334 | $83K |
| 76857 | <1% | 1,977 | $82K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 515 | $81K |
| 70496 | <1% | 284 | $81K | |
| 99386 | <1% | 575 | $79K | |
| 90651 | <1% | 2,925 | $78K | |
| 94060 | <1% | 413 | $78K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,604 | $78K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 71,715 | $76K |
| 90677 | <1% | 1,293 | $74K | |
| 36430 | <1% | 170 | $74K | |
| 97802 | <1% | 1,900 | $74K | |
| 85610 | <1% | 24,590 | $73K | |
| 76641 | <1% | 1,837 | $65K | |
| 70486 | <1% | 806 | $65K | |
| 97760 | <1% | 1,018 | $63K | |
| 92201 | <1% | 861 | $62K | |
| 82803 | <1% | 3,036 | $62K | |
| D0274 | Bitewings - four radiographic images | <1% | 2,766 | $61K |
| 88304 | <1% | 2,277 | $61K | |
| 84439 | <1% | 12,623 | $61K | |
| 92552 | <1% | 702 | $59K | |
| 83013 | <1% | 806 | $59K | |
| 85055 | <1% | 1,584 | $59K | |
| 85027 | <1% | 19,228 | $57K | |
| 86003 | <1% | 942 | $56K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,330 | $56K |
| 90670 | <1% | 5,421 | $55K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 9,079 | $53K |
| 82607 | <1% | 5,751 | $53K | |
| 96415 | <1% | 139 | $53K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 815 | $52K |
| 88112 | <1% | 1,290 | $52K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 17 | $50K |
| 90680 | <1% | 4,990 | $49K | |
| 76642 | <1% | 589 | $48K | |
| 96127 | <1% | 6,079 | $47K | |
| 84466 | <1% | 6,774 | $45K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 26,058 | $45K |
| 62323 | <1% | 100 | $45K | |
| 92610 | <1% | 326 | $44K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 20,915 | $44K |
| 81001 | <1% | 32,262 | $43K | |
| 87503 | <1% | 1,371 | $43K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 300 | $42K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,751 | $40K |
| 58558 | <1% | 26 | $39K | |
| D0210 | Intraoral - complete series of radiographic images | <1% | 1,234 | $39K |
| D0120 | Dental checkup, returning patient | <1% | 2,216 | $39K |
| 76000 | <1% | 367 | $37K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 16,751 | $36K |
| 88173 | <1% | 841 | $36K | |
| 90698 | <1% | 3,425 | $36K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,153 | $36K |
| 82728 | <1% | 4,193 | $36K | |
| 90633 | <1% | 3,454 | $35K | |
| 99177 | <1% | 983 | $35K | |
| 90461 | <1% | 4,460 | $34K | |
| 88360 | <1% | 486 | $34K | |
| 81025 | <1% | 10,674 | $34K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 3,526 | $33K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,509 | $33K |
| 93017 | <1% | 323 | $32K | |
| 92226 | <1% | 736 | $32K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 652 | $32K |
| 86803 | <1% | 7,109 | $31K | |
| 90697 | <1% | 1,314 | $31K | |
| 84146 | <1% | 2,044 | $29K | |
| 82670 | <1% | 1,041 | $29K | |
| 77065 | Tomosynthesis, mammo | <1% | 369 | $28K |
| 82805 | <1% | 771 | $28K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 275 | $28K |
| 62321 | <1% | 39 | $27K | |
| 52356 | <1% | 12 | $27K | |
| 77386 | <1% | 150 | $27K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 412 | $27K |
| 87340 | <1% | 5,722 | $27K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,765 | $26K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 515 | $25K |
| 90619 | <1% | 958 | $25K | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,980 | $24K |
| 90707 | <1% | 1,847 | $24K | |
| 90716 | <1% | 1,781 | $24K | |
| 97116 | <1% | 736 | $24K | |
| 50590 | <1% | 13 | $24K | |
| 84153 | <1% | 1,727 | $23K | |
| 90750 | <1% | 180 | $23K | |
| 76813 | <1% | 500 | $23K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 9,350 | $23K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 62 | $22K |
| 84702 | <1% | 6,356 | $22K | |
| 83540 | <1% | 7,274 | $22K | |
| 82746 | <1% | 2,436 | $21K | |
| 29125 | <1% | 91 | $21K | |
| 83001 | <1% | 1,438 | $21K | |
| C1819 | Surgical tissue localization and excision device (implantable) | <1% | 421 | $21K |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 1,176 | $21K |
| 90620 | <1% | 1,128 | $21K | |
| 29530 | <1% | 80 | $20K | |
| 77290 | <1% | 49 | $19K | |
| 83002 | <1% | 1,292 | $19K | |
| 84681 | <1% | 840 | $18K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 12 | $18K |
| D0140 | Limited oral evaluation - problem focused | <1% | 1,501 | $18K |
| 73562 | <1% | 3,415 | $17K | |
| 83525 | <1% | 1,786 | $17K | |
| 84436 | <1% | 3,624 | $16K | |
| 77066 | Tomosynthesis, mammo | <1% | 210 | $16K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 908 | $16K |
| 90723 | <1% | 1,812 | $16K | |
| 82962 | <1% | 11,529 | $16K | |
| 86592 | <1% | 8,145 | $16K | |
| 84403 | <1% | 940 | $16K | |
| 51702 | <1% | 41 | $16K | |
| 76870 | <1% | 426 | $15K | |
| 87147 | <1% | 5,176 | $15K | |
| 85730 | <1% | 18,770 | $15K | |
| C1769 | Guide wire | <1% | 1,720 | $15K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 307 | $15K |
| 76820 | <1% | 344 | $15K | |
| 84144 | <1% | 2,146 | $15K | |
| 90710 | <1% | 1,299 | $15K | |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 229 | $14K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,022 | $14K |
| 86359 | <1% | 503 | $14K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 11,024 | $14K |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 2,661 | $14K |
| 90648 | <1% | 1,535 | $14K | |
| 86317 | <1% | 2,917 | $14K | |
| 77280 | <1% | 28 | $14K | |
| 90656 | <1% | 1,033 | $14K | |
| 90696 | <1% | 1,256 | $13K | |
| 95911 | <1% | 131 | $13K | |
| 71250 | <1% | 109 | $13K | |
| 87081 | <1% | 9,806 | $13K | |
| 81003 | <1% | 23,789 | $13K | |
| 99243 | <1% | 85 | $13K | |
| 73030 | <1% | 2,517 | $13K | |
| 95813 | <1% | 47 | $12K | |
| 36410 | <1% | 728 | $12K | |
| 95708 | <1% | 33 | $12K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 129 | $12K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 384 | $12K |
| 90734 | <1% | 1,160 | $12K | |
| 86762 | <1% | 1,969 | $11K | |
| D0330 | Panoramic radiographic image | <1% | 246 | $11K |
| 83970 | <1% | 279 | $11K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 934 | $11K |
| 92235 | <1% | 92 | $11K | |
| 86765 | <1% | 2,039 | $11K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,546 | $11K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 621 | $11K |
| 86140 | <1% | 11,593 | $11K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 428 | $10K |
| 82533 | <1% | 557 | $10K | |
| 86360 | <1% | 503 | $10K | |
| 76885 | <1% | 250 | $10K | |
| D9310 | <1% | 361 | $10K | |
| 82043 | <1% | 2,805 | $9K | |
| 99383 | <1% | 63 | $9K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 292 | $9K |
| 0001A | <1% | 232 | $9K | |
| 77332 | <1% | 28 | $9K | |
| 0124A | <1% | 224 | $9K | |
| 73110 | <1% | 3,261 | $9K | |
| 76536 | <1% | 95 | $8K | |
| 29515 | <1% | 29 | $8K | |
| 36416 | <1% | 498 | $8K | |
| 94726 | <1% | 83 | $8K | |
| 76514 | <1% | 197 | $7K | |
| 84484 | <1% | 12,199 | $7K | |
| 0071A | <1% | 180 | $7K | |
| 86696 | <1% | 1,886 | $7K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 20 | $7K |
| 99242 | <1% | 47 | $7K | |
| 73610 | <1% | 3,315 | $7K | |
| 84479 | <1% | 2,450 | $7K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,988 | $7K |
| 25605 | <1% | 12 | $7K | |
| 94729 | <1% | 149 | $7K | |
| 87660 | <1% | 626 | $7K | |
| 87480 | <1% | 608 | $7K | |
| 92225 | <1% | 57 | $7K | |
| 96402 | <1% | 133 | $7K | |
| 87493 | <1% | 255 | $7K | |
| 77080 | <1% | 79 | $6K | |
| 87510 | <1% | 594 | $6K | |
| D1120 | Dental cleaning, child | <1% | 237 | $6K |
| 86800 | <1% | 571 | $6K | |
| 73564 | <1% | 374 | $6K | |
| 87186 | <1% | 4,209 | $6K | |
| 73130 | <1% | 3,419 | $6K | |
| 77295 | <1% | 40 | $6K | |
| 82785 | <1% | 654 | $6K | |
| 82784 | <1% | 814 | $6K | |
| 83690 | <1% | 16,824 | $6K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 887 | $6K |
| 29130 | <1% | 24 | $6K | |
| 86376 | <1% | 651 | $6K | |
| 72193 | <1% | 43 | $6K | |
| 96376 | <1% | 1,682 | $6K | |
| 84703 | <1% | 13,340 | $6K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 1,469 | $6K |
| 10060 | <1% | 15 | $6K | |
| 83020 | <1% | 1,111 | $6K | |
| 86704 | <1% | 1,641 | $6K | |
| 92250 | <1% | 66 | $6K | |
| 0072A | <1% | 138 | $6K | |
| 86709 | <1% | 660 | $6K | |
| D9430 | <1% | 427 | $5K | |
| 73630 | <1% | 3,068 | $5K | |
| 84550 | <1% | 1,745 | $5K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $5K |
| 72100 | <1% | 998 | $5K | |
| 82947 | <1% | 1,996 | $5K | |
| 85651 | <1% | 4,096 | $5K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 13 | $5K |
| 93971 | <1% | 65 | $5K | |
| 51701 | <1% | 41 | $5K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,911 | $5K |
| D9995 | <1% | 202 | $5K | |
| 99382 | <1% | 27 | $5K | |
| 84481 | <1% | 655 | $5K | |
| 86735 | <1% | 1,295 | $5K | |
| 73080 | <1% | 1,804 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 11,810 | $4K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 32 | $4K |
| 93325 | <1% | 78 | $4K | |
| 86235 | <1% | 261 | $4K | |
| 86787 | <1% | 1,035 | $4K | |
| J1335 | Injection, ertapenem sodium, 500 mg | <1% | 3,713 | $4K |
| 88300 | <1% | 854 | $4K | |
| 0002A | <1% | 105 | $4K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,970 | $4K |
| 99241 | <1% | 27 | $4K | |
| 86160 | <1% | 240 | $4K | |
| 0154A | <1% | 105 | $4K | |
| 82985 | <1% | 760 | $4K | |
| 83550 | <1% | 7,004 | $4K | |
| 86038 | <1% | 978 | $4K | |
| 36406 | <1% | 241 | $4K | |
| 83993 | <1% | 540 | $4K | |
| 84402 | <1% | 336 | $4K | |
| 70498 | <1% | 217 | $4K | |
| 82627 | <1% | 515 | $4K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 573 | $4K |
| 84145 | <1% | 4,360 | $4K | |
| 74420 | <1% | 15 | $4K | |
| 95886 | <1% | 108 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,790 | $4K |
| 0003A | <1% | 87 | $4K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 675 | $4K |
| 82550 | <1% | 2,987 | $4K | |
| 96368 | <1% | 231 | $4K | |
| 90675 | <1% | 59 | $4K | |
| 88321 | <1% | 53 | $3K | |
| 83735 | <1% | 6,496 | $3K | |
| 87070 | <1% | 1,974 | $3K | |
| 86695 | <1% | 1,059 | $3K | |
| 90744 | <1% | 321 | $3K | |
| 96417 | <1% | 845 | $3K | |
| 82977 | <1% | 812 | $3K | |
| 87806 | <1% | 168 | $3K | |
| 83605 | <1% | 8,682 | $3K | |
| 87040 | <1% | 4,951 | $3K | |
| 90746 | <1% | 94 | $3K | |
| 82157 | <1% | 167 | $3K | |
| 90688 | <1% | 373 | $3K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,406 | $3K |
| 73502 | <1% | 582 | $3K | |
| 97803 | <1% | 79 | $3K | |
| 87641 | <1% | 277 | $3K | |
| 87077 | <1% | 1,355 | $3K | |
| 86431 | <1% | 635 | $3K | |
| 90381 | <1% | 73 | $3K | |
| 73590 | <1% | 1,408 | $3K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 70 | $3K |
| 93798 | <1% | 79 | $3K | |
| 84480 | <1% | 598 | $3K | |
| 77012 | <1% | 16 | $3K | |
| 82105 | <1% | 613 | $3K | |
| 84112 | <1% | 67 | $3K | |
| 82950 | <1% | 1,016 | $3K | |
| 73700 | <1% | 13 | $2K | |
| 86923 | <1% | 93 | $2K | |
| 82677 | <1% | 239 | $2K | |
| 82248 | <1% | 1,267 | $2K | |
| 73560 | <1% | 598 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 42 | $2K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 817 | $2K |
| 80050 | General health panel | <1% | 396 | $2K |
| 80329 | <1% | 1,260 | $2K | |
| 83516 | <1% | 743 | $2K | |
| 99384 | <1% | 13 | $2K | |
| 84432 | <1% | 151 | $2K | |
| 90732 | <1% | 54 | $2K | |
| 76999 | <1% | 26 | $2K | |
| 84305 | <1% | 120 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,646 | $2K |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 727 | $2K |
| 76821 | <1% | 50 | $2K | |
| 72170 | <1% | 826 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 15,698 | $2K |
| 96411 | <1% | 61 | $2K | |
| 85379 | <1% | 2,377 | $2K | |
| 86255 | <1% | 337 | $2K | |
| 99245 | <1% | 12 | $2K | |
| 94760 | <1% | 264 | $2K | |
| 86304 | <1% | 75 | $2K | |
| 84445 | <1% | 71 | $2K | |
| 86200 | <1% | 307 | $2K | |
| 82465 | <1% | 606 | $2K | |
| 86225 | <1% | 344 | $2K | |
| 83615 | <1% | 1,236 | $2K | |
| 0081A | <1% | 43 | $2K | |
| 82570 | <1% | 1,841 | $2K | |
| D4341 | <1% | 14 | $2K | |
| 77072 | <1% | 156 | $1K | |
| 82150 | <1% | 596 | $1K | |
| 74018 | <1% | 1,517 | $1K | |
| C1776 | Joint device (implantable) | <1% | 15 | $1K |
| 84100 | <1% | 3,549 | $1K | |
| 88312 | <1% | 40 | $1K | |
| 83631 | <1% | 219 | $1K | |
| C1874 | Stent, coated/covered, with delivery system | <1% | 80 | $1K |
| 84156 | <1% | 1,661 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,059 | $1K |
| 82247 | <1% | 415 | $1K | |
| 90647 | <1% | 158 | $1K | |
| 82378 | <1% | 69 | $1K | |
| D1206 | Topical application of fluoride varnish | <1% | 62 | $1K |
| 82565 | <1% | 1,034 | $1K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 508 | $1K |
| 73090 | <1% | 1,380 | $1K | |
| 99429 | <1% | 97 | $1K | |
| 72110 | <1% | 388 | $1K | |
| 72081 | <1% | 148 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 15 | $1K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,667 | $1K |
| D9210 | <1% | 278 | $1K | |
| 87205 | <1% | 1,736 | $1K | |
| 82330 | <1% | 2,131 | $1K | |
| 88311 | <1% | 39 | $984.80 | |
| D9110 | <1% | 78 | $953.89 | |
| 73140 | <1% | 1,362 | $953.69 | |
| C1781 | Mesh (implantable) | <1% | 50 | $944.30 |
| 72083 | <1% | 78 | $931.39 | |
| 86039 | <1% | 225 | $914.19 | |
| 97763 | <1% | 13 | $880.70 | |
| 84704 | <1% | 239 | $871.04 | |
| J1741 | Injection, ibuprofen, 100 mg | <1% | 438 | $833.60 |
| C1758 | Catheter, ureteral | <1% | 107 | $832.97 |
| 73521 | <1% | 138 | $822.96 | |
| 80320 | <1% | 3,067 | $803.79 | |
| 77061 | <1% | 14 | $769.52 | |
| 84460 | <1% | 954 | $760.84 | |
| D9990 | <1% | 41 | $759.27 | |
| 90743 | <1% | 46 | $752.58 | |
| 85652 | <1% | 4,927 | $743.96 | |
| 95885 | <1% | 33 | $716.92 | |
| 85045 | <1% | 504 | $697.27 | |
| 0054A | <1% | 19 | $668.13 | |
| 84450 | <1% | 841 | $663.89 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 14 | $636.43 |
| 86336 | <1% | 186 | $623.53 | |
| 99406 | <1% | 12 | $619.36 | |
| 73000 | <1% | 79 | $585.05 | |
| 82270 | <1% | 699 | $580.65 | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 56 | $546.15 |
| 87640 | <1% | 238 | $521.34 | |
| 87338 | <1% | 98 | $519.61 | |
| 0082A | <1% | 12 | $516.00 | |
| 72040 | <1% | 51 | $515.10 | |
| 75574 | <1% | 30 | $486.94 | |
| 84132 | <1% | 1,105 | $468.08 | |
| 85660 | <1% | 1,025 | $462.10 | |
| 80179 | <1% | 966 | $456.74 | |
| 82652 | <1% | 47 | $448.60 | |
| 0074A | <1% | 12 | $436.00 | |
| 76825 | <1% | 13 | $418.22 | |
| 84520 | <1% | 519 | $417.77 | |
| 76827 | <1% | 13 | $412.74 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,469 | $392.90 |
| 87185 | <1% | 226 | $390.01 | |
| 90694 | <1% | 31 | $372.07 | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 283 | $362.99 |
| 73552 | <1% | 135 | $361.81 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,950 | $346.42 |
| 82272 | <1% | 233 | $333.41 | |
| 83037 | <1% | 102 | $320.68 | |
| 82390 | <1% | 42 | $318.93 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 891 | $314.10 |
| 82103 | <1% | 27 | $309.25 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 13 | $299.51 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 768 | $296.83 |
| 90685 | <1% | 16 | $289.62 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,655 | $286.75 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 765 | $280.91 |
| 85014 | <1% | 2,115 | $268.98 | |
| 90380 | <1% | 13 | $262.32 | |
| 83498 | <1% | 14 | $258.47 | |
| 86301 | <1% | 13 | $255.48 | |
| 91319 | <1% | 16 | $252.56 | |
| 72082 | <1% | 15 | $250.17 | |
| 90672 | <1% | 12 | $234.68 | |
| 82172 | <1% | 14 | $232.34 | |
| D0170 | <1% | 27 | $231.81 | |
| 86618 | <1% | 15 | $226.49 | |
| 90653 | <1% | 37 | $220.50 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,452 | $208.11 |
| 73070 | <1% | 211 | $201.78 | |
| 86694 | <1% | 248 | $199.17 | |
| 86300 | <1% | 13 | $196.78 | |
| 86021 | <1% | 12 | $186.91 | |
| 86060 | <1% | 40 | $174.72 | |
| 72070 | <1% | 25 | $143.85 | |
| 82104 | <1% | 13 | $141.52 | |
| 84295 | <1% | 785 | $141.02 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,100 | $139.06 |
| 82435 | <1% | 777 | $128.67 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 10,624 | $127.61 |
| 86644 | <1% | 26 | $123.71 | |
| 85384 | <1% | 215 | $119.93 | |
| 84165 | <1% | 15 | $117.93 | |
| 86141 | <1% | 29 | $117.68 | |
| 94664 | <1% | 642 | $115.84 | |
| 73060 | <1% | 301 | $112.25 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 75 | $109.80 |
| 71101 | <1% | 164 | $101.46 | |
| 86705 | <1% | 12 | $100.45 | |
| 84155 | <1% | 42 | $89.21 | |
| 85347 | <1% | 38 | $85.34 | |
| 86645 | <1% | 36 | $84.79 | |
| 86580 | <1% | 15 | $83.42 | |
| 87075 | <1% | 39 | $80.14 | |
| 82951 | <1% | 13 | $79.75 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 2,020 | $77.82 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,143 | $75.77 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,333 | $71.62 |
| 82657 | <1% | 66 | $69.24 | |
| 86777 | <1% | 20 | $62.33 | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 13 | $59.48 |
| J7642 | Glycopyrrolate, inhalation solution, compounded product, administered through dme, concentrated form, per milligram | <1% | 322 | $58.40 |
| 82656 | <1% | 14 | $52.91 | |
| 91312 | <1% | 16 | $45.72 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 6,394 | $44.98 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,042 | $40.60 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,632 | $39.87 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 224 | $39.75 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 126 | $33.86 |
| J1094 | Injection, dexamethasone acetate, 1 mg | <1% | 633 | $30.41 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 225 | $26.86 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,254 | $26.04 |
| C9399 | Unclassified drugs or biologicals | <1% | 1,298 | $20.70 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 210 | $19.80 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,573 | $16.37 |
| 84478 | <1% | 12 | $16.09 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 36 | $14.16 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 16 | $13.74 |
| 83930 | <1% | 30 | $12.08 | |
| 83021 | <1% | 54 | $11.73 | |
| G0008 | Administration of influenza virus vaccine | <1% | 62 | $11.67 |
| 86708 | <1% | 24 | $10.10 | |
| 82010 | <1% | 69 | $7.20 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 283 | $5.51 |
| 88720 | <1% | 68 | $5.02 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 452 | $3.74 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 295 | $3.10 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 120 | $2.13 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,858 | $2.12 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 19 | $1.99 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 55 | $1.01 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 81 | $0.84 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 240 | $0.10 |
| 99080 | 0% | 5,700 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 63 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 38 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 40 | $0.00 |
| 69210 | 0% | 29 | $0.00 | |
| 3E03329 | 0% | 61 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 31 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 19 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 12 | $0.00 |
| 29826 | 0% | 12 | $0.00 | |
| 87206 | 0% | 12 | $0.00 | |
| 87449 | 0% | 26 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 18 | $0.00 |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 30 | $0.00 |
| 77417 | 0% | 44 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBRESLIN, MICHAEL (GROUP SVP, CFO & TREASURER)
Parent organizationNYP COMMUNITY PROGRAMS, INC.
| Provider | Location | Paid |
|---|---|---|
| The New York and Presbyterian Hospital | New York, NY | $454.95M |
| The New York and Presbyterian Hospital | New York, NY | $207.37M |
| New York and Presbyterian Hospital | Brooklyn, NY | $49.52M |
| The New York and Presbyterian Hospital | New York, NY | $6.29M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.